2Q EARNINGS: New drugs boost J&J's profit
This article was originally published in Scrip
Executive Summary
Johnson & Johnson’s drug sales jumped 12% to $7 billion in the second quarter, boosted by strong growth from new treatments for cancer, autoimmune diseases and other conditions.